Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen

Evidence that simian virus 40 (SV40) is associated with human mesotheliomas, osteosarcomas, and brain tumors suggests that a recombinant vaccine directed against lethal cancers expressing SV40 T antigen (Tag) could have clinical utility. To address this potential need, we designed a novel vaccinia v...

Full description

Saved in:

Bibliographic Details
Published in:	JNCI : Journal of the National Cancer Institute Vol. 91; no. 2; p. 169
Main Authors:	Xie, Y C, Hwang, C, Overwijk, W, Zeng, Z, Eng, M H, Mulé, J J, Imperiale, M J, Restifo, N P, Sanda, M G
Format:	Journal Article
Language:	English
Published:	United States 20.01.1999
Subjects:	Antineoplastic Agents - chemical synthesis Antineoplastic Agents - immunology Antineoplastic Agents - pharmacology Blotting, Western Cancer Vaccines - chemical synthesis Cancer Vaccines - immunology Cancer Vaccines - pharmacology Defective Viruses - genetics Genetic Vectors Humans Neoplasms - immunology Neoplasms - therapy Recombinant Proteins - chemical synthesis Recombinant Proteins - immunology Recombinant Proteins - pharmacology Reverse Transcriptase Polymerase Chain Reaction Simian virus 40 - immunology T-Lymphocytes - immunology Tumor Cells, Cultured Vaccinia virus - genetics
ISSN:	0027-8874
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!